Henry Schein Reports Q4 Results, Full-Year EPS Hits $3.27
Medical and dental supply distributor Henry Schein (NASDAQ: HSIC) filed its quarterly results with the SEC on February 24, 2026, reporting full-year 2025 earnings per share of $3.27 and annual revenue of $13.2 billion.
Key Numbers
The Melville, New York-based healthcare distribution giant posted fiscal 2025 diluted earnings per share of $3.27, with fourth-quarter results contributing to the full-year performance. Annual revenue reached $13.2 billion for the year ended December 27, 2025, maintaining the company's position as one of the largest distributors of healthcare products and services to office-based dental and medical practitioners.
Net income for fiscal 2025 totaled $400 million, reflecting the company's operational performance across its dental, medical, and technology segments. The fourth quarter capped a year where Henry Schein navigated ongoing market dynamics in the post-pandemic healthcare distribution landscape.
Quarterly revenue of $3.38 billion in the most recent period demonstrated the company's consistent revenue generation capabilities. The results come as Henry Schein continues to serve approximately 1 million customers worldwide, including dental practices, medical offices, and alternate care sites.
What Management Said
While specific management commentary was not included in the initial 8-K filing, the company's formal filing with the Securities and Exchange Commission signals completion of another fiscal year for the Fortune 500 company. The filing, signed by Senior Vice President and Chief Financial Officer Ronald N. South, represents the company's official quarterly disclosure to shareholders and regulators.
Henry Schein typically provides detailed commentary on market conditions, operational initiatives, and strategic priorities during its earnings conference call, which generally follows the initial filing. The company has historically focused on themes including digital dentistry adoption, medical market expansion, and technology platform development.
The filing indicates no unusual items or one-time charges that would require separate disclosure under SEC regulations, suggesting the reported results reflect core operational performance.
What to Watch
Investors should monitor several key areas as Henry Schein moves into fiscal 2026. The company's ability to maintain margins amid potential supply chain pressures remains critical, particularly given its role as a distribution intermediary between manufacturers and healthcare providers.
The dental segment, traditionally Henry Schein's largest business unit, faces ongoing questions about patient traffic normalization and equipment upgrade cycles. Practice consolidation trends and the growth of dental service organizations (DSOs) continue to reshape the customer landscape.
In the medical segment, Henry Schein's expansion into specialty markets including dermatology, gastroenterology, and podiatry represents a potential growth driver. The company's technology and value-added services offerings, which help practices with operational efficiency and patient engagement, could become increasingly important differentiators.
Regulatory changes in healthcare reimbursement and potential shifts in medical supply purchasing patterns through group purchasing organizations also warrant attention. As one of the few scaled players in healthcare distribution, Henry Schein's results often provide insight into broader healthcare utilization trends.
The company's international operations, which historically account for approximately one-third of revenue, face currency headwinds and varying regional market dynamics that could impact future results.
*Source: Henry Schein Form 8-K filed with the SEC on February 24, 2026*
*StockCliff Research*